Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-117.30M | $-2.29 |
| 2024 | $0.00 | $-55.14M | $-1.46 |
| 2023 | $0.00 | $-99.92M | $-4.24 |
| 2022 | $0.00 | $-24.46M | $-1.84 |
| 2021 | $0.00 | $-23.44M | $-0.01 |
Social Signal Score
Earnings
Mon, Sep 14(in 4 weeks)
Consensus estimate $-0.47 per share
Typical surprise -2.6% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Jun 15$-0.43 vs $-0.48beat
- Mon, Mar 9$-0.44 vs $-0.55beat
- Mon, Dec 22$-0.73 vs $-0.57miss
- Thu, Sep 11$-0.57 vs $-0.50miss
- Thu, Jun 12$-0.51 vs $-0.50miss
- Mon, Mar 10$-0.48 vs $-0.37miss
Estimates and results for ENGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
ENGNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (2)
- Newsmarketbeat.com·2d ago·Neutral
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market enGene NASDAQ: ENGN outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, or NMIBC, market, citing market research that it believes supports a larger addressable patient population and greater use of treatment sequencing before radical cystectomy.
View source ↗ - Newsseekingalpha.com·3d ago·Positive
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript
View source ↗